MXPA05009435A - Selective cytokine inhibitory drugs for treating disorders of the central nervous system. - Google Patents
Selective cytokine inhibitory drugs for treating disorders of the central nervous system.Info
- Publication number
- MXPA05009435A MXPA05009435A MXPA05009435A MXPA05009435A MXPA05009435A MX PA05009435 A MXPA05009435 A MX PA05009435A MX PA05009435 A MXPA05009435 A MX PA05009435A MX PA05009435 A MXPA05009435 A MX PA05009435A MX PA05009435 A MXPA05009435 A MX PA05009435A
- Authority
- MX
- Mexico
- Prior art keywords
- nervous system
- central nervous
- cytokine inhibitory
- selective cytokine
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Methods of treating, preventing and/or managing central nervous system disorders, such as Parkinson disease, Alzheimer disease, mild cognitive impairment, Huntington disease, Amytophic Lateral Sclerosis, depression and defective long-term memory, and related syndromes are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45237403P | 2003-03-06 | 2003-03-06 | |
PCT/US2004/006782 WO2004080393A2 (en) | 2003-03-06 | 2004-03-05 | Selective cytokine inhibitory drugs for treating disorders of the central nervous system |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05009435A true MXPA05009435A (en) | 2005-11-23 |
Family
ID=32990646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05009435A MXPA05009435A (en) | 2003-03-06 | 2004-03-05 | Selective cytokine inhibitory drugs for treating disorders of the central nervous system. |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1605935A4 (en) |
JP (1) | JP2006519875A (en) |
KR (1) | KR100831545B1 (en) |
CN (1) | CN1780616B (en) |
AU (1) | AU2004220607B2 (en) |
BR (1) | BRPI0408113A (en) |
CA (1) | CA2517845A1 (en) |
IL (1) | IL170710A0 (en) |
MX (1) | MXPA05009435A (en) |
NZ (1) | NZ542408A (en) |
WO (1) | WO2004080393A2 (en) |
ZA (1) | ZA200507322B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
BR112012019923A2 (en) | 2010-02-09 | 2016-08-09 | Univ Johns Hopkins | methods and compositions for improving cognitive function |
CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
EP2968220B1 (en) | 2013-03-15 | 2021-05-05 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
CN107810002B (en) | 2015-05-22 | 2021-01-05 | 艾吉因生物股份有限公司 | Extended release pharmaceutical compositions of levetiracetam |
KR102549684B1 (en) * | 2017-10-18 | 2023-06-29 | 인트라바이오 리미티드 | Treatments for neurodegenerative diseases |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
JP2023549174A (en) * | 2020-11-04 | 2023-11-22 | グリアセルテック・インコーポレイテッド | Composition for preventing or treating neuroinflammatory diseases containing chlorpromazine |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
AR003951A1 (en) * | 1995-05-26 | 1998-09-30 | Pfizer | SYNERGIC PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF PARKINSON'S DISEASE AND COMPOSITIONS TO PREPARE IT. |
US5728845A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
JP3568749B2 (en) * | 1996-12-17 | 2004-09-22 | 株式会社デンソー | Dry etching method for semiconductor |
CN1265590A (en) * | 1997-07-31 | 2000-09-06 | 赛尔金有限公司 | Substituted alkanohydroxamic acid and method of reducing TNF 'alpha' levels |
US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US6177077B1 (en) * | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
US6471961B1 (en) * | 1999-02-24 | 2002-10-29 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US6623736B2 (en) * | 2000-05-02 | 2003-09-23 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
WO2003080048A1 (en) * | 2002-03-20 | 2003-10-02 | Celgene Corporation | (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
AU2003262187A1 (en) * | 2002-04-12 | 2003-10-27 | Celgene Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
-
2004
- 2004-03-05 CN CN2004800118192A patent/CN1780616B/en not_active Expired - Fee Related
- 2004-03-05 ZA ZA200507322A patent/ZA200507322B/en unknown
- 2004-03-05 NZ NZ542408A patent/NZ542408A/en unknown
- 2004-03-05 KR KR1020057016598A patent/KR100831545B1/en not_active IP Right Cessation
- 2004-03-05 CA CA002517845A patent/CA2517845A1/en not_active Abandoned
- 2004-03-05 AU AU2004220607A patent/AU2004220607B2/en not_active Ceased
- 2004-03-05 EP EP04717992A patent/EP1605935A4/en not_active Withdrawn
- 2004-03-05 WO PCT/US2004/006782 patent/WO2004080393A2/en active Application Filing
- 2004-03-05 JP JP2006509174A patent/JP2006519875A/en active Pending
- 2004-03-05 BR BRPI0408113-7A patent/BRPI0408113A/en not_active IP Right Cessation
- 2004-03-05 MX MXPA05009435A patent/MXPA05009435A/en not_active Application Discontinuation
-
2005
- 2005-09-06 IL IL170710A patent/IL170710A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR100831545B1 (en) | 2008-05-21 |
NZ542408A (en) | 2009-03-31 |
EP1605935A4 (en) | 2009-05-20 |
EP1605935A2 (en) | 2005-12-21 |
CN1780616A (en) | 2006-05-31 |
WO2004080393A2 (en) | 2004-09-23 |
AU2004220607A1 (en) | 2004-09-23 |
CA2517845A1 (en) | 2004-09-23 |
IL170710A0 (en) | 2011-08-01 |
KR20050109971A (en) | 2005-11-22 |
CN1780616B (en) | 2010-05-12 |
WO2004080393A3 (en) | 2004-12-02 |
JP2006519875A (en) | 2006-08-31 |
ZA200507322B (en) | 2007-03-28 |
BRPI0408113A (en) | 2006-03-01 |
AU2004220607B2 (en) | 2009-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005043971A3 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | |
WO2005046318A3 (en) | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders | |
WO2005097125A3 (en) | Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease | |
BRPI0315315B8 (en) | ||
TW200631578A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury | |
WO2000010551A3 (en) | Methods of using and compositions comprising dopamine reuptake inhibitors | |
MX2007006066A (en) | Jnk inhibitors for treatment of cns injury. | |
WO2008008474A3 (en) | Compositions and methods for the treatment of chronic pain conditions | |
WO2004037207A3 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | |
WO2004043378A3 (en) | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases | |
WO2005002582A3 (en) | Trp-p8 active compounds and therapeutic treatment methods | |
WO2005046593A3 (en) | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. | |
MXPA06002722A (en) | A pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti inflammatory drug. | |
UA103791C2 (en) | Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis | |
MXPA05009435A (en) | Selective cytokine inhibitory drugs for treating disorders of the central nervous system. | |
MXPA05012358A (en) | Pharmaceutical combination comprising modafinil and another drug. | |
WO2004034962A3 (en) | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome | |
WO2005094218A3 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system | |
WO2006064228A3 (en) | Thiazolopyramidine compounds for the modulation of chemokine receptor activity | |
WO2005039497A3 (en) | Methods and compositions comprising thalidomide for treatment of fibromyalgia | |
WO2004041190A3 (en) | Composition for the treatment of macular degenration | |
WO2004037199A3 (en) | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain | |
WO2005065372A3 (en) | Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases | |
WO2005110085A3 (en) | Use of selective cytokine inhibitory drugs in myelodysplastic syndromes | |
WO2004029025A3 (en) | Methods and compositions for the treatment of autoimmune disorders using clofarabine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |